Présentation de l'entreprise
Xilio Therapeutics, Inc. operates as a clinical-stage biotechnology entity dedicated to the discovery and development of tumor-activated immuno-oncology therapies, with a specific focus on its checkpoint inhibitor program that includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb currently in Phase 2 clinical trials. The company functions within the healthcare sector and specifically the biotechnology industry, positioning itself to leverage advancements in immuno-oncology to create therapies that activate the immune system specifically within the tumor microenvironment. As of the latest reporting period, the organization employs 76 individuals and maintains a total market capitalization of 50.25M dollars, while reporting a trailing twelve-month revenue of 43.77M dollars. These valuation and revenue metrics indicate that Xilio Therapeutics remains a small-cap entity with a market capitalization significantly below the major pharmaceutical peers, reflecting its status as an early-to-mid-stage biotech firm whose revenue generation is currently heavily dependent on its pipeline progress rather than established commercial sales.
Santé financière
The financial performance of Xilio Therapeutics, Inc. over the trailing twelve months shows a revenue of 43.77M dollars against a net income of -35,036,000 dollars and an EBITDA of -40,441,000 dollars, revealing a cost structure where operating expenses substantially exceed gross margins. Despite the significant net loss, the company reports a positive free cash flow of 8.03M dollars, which suggests a degree of financial flexibility allowing the firm to manage operational burn while potentially optimizing capital allocation through non-operating activities or asset utilization. The margin profile displays a gross margin of 100.0%, indicative of a service-based or pre-commercialization revenue model with no cost of goods sold, contrasted by a severe operating margin of -86.5% and a profit margin of -80.1% that highlight the intense R&D and administrative costs inherent in clinical-stage development. Liquidity and solvency are characterized by a cash balance of 137.53M dollars against a debt load of 6.95M dollars, resulting in a debt-to-equity ratio of 19.71 that technically indicates leverage but must be viewed in the context of the massive cash reserve providing a substantial safety net. The current ratio stands at 2.58, indicating a strong position in short-term liquidity where current assets are more than twice the current liabilities, ensuring the ability to meet obligations without immediate refinancing pressure. Furthermore, the return on equity is -132.5% and the return on assets is -23.2%, metrics that reveal the company is currently in a capital-intensive growth phase where management is prioritizing asset accumulation and pipeline advancement over immediate shareholder profitability.
Évaluation de la valorisation
Valuation metrics for Xilio Therapeutics, Inc. present a complex picture typical of clinical-stage biotechnology firms, with a trailing P/E ratio of N/A due to the absence of net income and a forward P/E of -14.98 derived from negative earnings projections. The negative forward P/E implies that the market prices in a period of continued losses, suggesting that earnings are not yet expected to be profitable within the near-term forecast horizon. The price-to-book ratio is recorded at 1.12, indicating that the market values the company slightly above its book value, which is a common valuation multiple for biotech firms where intangible assets and pipeline potential are not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.15 and an EV/EBITDA of 1.99, figures that suggest the company is trading at a premium relative to its sales but at a low multiple relative to enterprise value compared to mature pharmaceutical companies. The stock has exhibited a 52-week high of 16.52 dollars and a 52-week low of 6.47 dollars, with the current price metrics suggesting volatility within this range but lacking a clear trend without external catalysts. The beta value is -0.12, a highly unusual negative figure that indicates the stock price moves inversely to the broader market or possesses extremely low correlation to general market movements, effectively acting as a non-systematic asset in terms of volatility relative to the broader market index.
Growth & Income
Revenue growth year-over-year has surged to 693.9%, reflecting the likely inclusion of milestone payments, licensing deals, or initial commercial recognition as the company transitions from pure research to clinical validation, whereas earnings growth is listed as N/A due to the persistent negative net income. The divergence between explosive revenue growth and negative earnings growth is typical for the biotechnology sector, implying that top-line expansion is currently outpacing the ability to generate bottom-line profitability. As a non-dividend payer, Xilio Therapeutics, Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all earnings and directs capital toward research, development, and operational expansion rather than distributing income to shareholders. This reinvestment strategy is consistent with the life cycle of a clinical-stage company that must preserve cash to advance its immuno-oncology pipeline. The overall growth and income profile is defined by high revenue expansion driven by strategic transactions or new revenue streams, combined with a complete absence of dividend income and negative earnings, creating a high-risk, high-reward equity structure reliant on future commercialization success.